

Through more than 70 years of business operations and consistent strategic decisions, the Krka Group has become one of the world's leading generic pharmaceutical companies.




Krka Group – financial highlights for 2025




Krka Group presentation

Since its establishment in 1954, Krka has grown through steady sales growth, continuous investment, in-house development, and strong business performance into one of the world's **leading innovative generic pharmaceutical** companies with a highly diversified sales structure. **International markets account for 94% of the Krka Group's total sales.** The Krka Group operates **several production sites worldwide**, with its main site located in Slovenia.



SALES BY REGION



Krka's share is the most traded share on the Ljubljana Stock Exchange

Over the past ten years, the dividend has increased by an average of approximately **13% per year**. We have established a share buyback programme and currently hold approximately 7.5% of all issued shares.

MARKET CAPITALISATION <small>(as at 31 Mar 2026)</small>	PRICE-EARNINGS (P/E) <small>(as at 31 Dec 2025)</small>	RETURN ON EQUITY (ROE) <small>(as at 31 Dec 2025)</small>	KRKA IS A DIVIDEND ARISTOCRAT. WE HAVE BEEN INCREASING THE DIVIDEND FOR 26 YEARS
EUR 7.6 bn	15.4x	17.5%	

The strength of our in-house expertise


Krka has more than **13,000 employees** who contribute to value creation every day.

Global presence

With its medicines, the Krka Group helps treat the most common diseases of our time for more than **100 million** people in over **70 countries**.

Three pillars of the 2026–2030 Krka Group Development Strategy

All processes within the Krka Group are strategically oriented towards supporting the company's growth and development and achieving strong business performance.



Key strategic objectives




Krka brand prescription pharmaceuticals are our most important products

Each year, the Krka Group manufactures **19 billion units** of products from across a wide range of therapeutic areas. In our commitment to health, we provide a broad range of high-quality prescription pharmaceuticals, non-prescription products and animal health products. The largest share of our product range consists of medicines for the treatment of chronic diseases.


Share

- 83.2%** Prescription pharmaceuticals
EUR **1,691.7 m** (+8%)
- 8.5%** Non-prescription products
EUR **173.5 m** (+1%)
- 5.6%** Animal health products
EUR **114.7 m** (+3%)
- 2.7%** Health resort and tourist services
EUR **54.2 m** (+10%)



Therapeutic areas of prescription pharmaceuticals

- 55%** CVS – cardiovascular system
- 13%** CNS – central nervous system
- 11%** Gastrointestinal tract
- 21%** Other



Continuous investment in R&D

- 10%** of revenue for research and development
- > 800** experts involved in research and development
- > 170** of new products in development

Extensive product range

Krka offers more than **1,000 products**. In 2025, we further strengthened our portfolio with **17 new products** tailored to patients' needs.

Innovations for the future

In 2025, we allocated **EUR 188 million** to research and development.

Combination medicines (SPCs) already account for approximately one third of all products sold

Krka is a pioneer in the field of SPCs, which combine multiple active pharmaceutical ingredients in a single tablet and enable simpler, more effective and more sustainable treatment for patients. Our range of products already includes more than 150 SPCs.

ESG rating




Vertical integration – from active ingredient to finished product



Medium-term stable business growth and trend



Long-term stable business growth



Revenue CAGR (2005–2025)	7.2%
Net income CAGR (2005–2025)	9.0%
Global pharmaceutical market CAGR (2005–2024), source: Statista	5.8%

Contact us

Krka, d. d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Phone: **+386 (0)7 311 75 91**
Email: **finance@krka.biz**
www.krka.si

Disclaimer

This presentation has been prepared by Krka, d. d., Novo mesto (hereinafter: the Company) solely for informational purposes. It does not provide a complete overview of the Company's operations and does not include all information that may be relevant for decision-making. The information and opinions contained herein are valid as of the date of this presentation and are subject to change without prior notice. Neither the Company nor its affiliated persons assume any obligation to update or supplement the information contained herein. The information presented herein should not be relied upon as the sole basis for making decisions. The Company does not accept any liability for any damage or loss arising from the use of this presentation. This presentation does not constitute an offer to buy or sell securities. Statements regarding future events are based on current assessments and assumptions and involve risks and uncertainties; therefore, actual results may differ materially from those expressed or implied.